INT258556

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.48
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (BRAF) plasma membrane (BRAF) nucleus (BRAF)
cytoplasm (BRAF)
Anatomy Link Frequency
thyroid 2
BRAF (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 59.36 Quite High
palliative 5 26.68 Quite Low
withdrawal 8 5.00 Very Low Very Low Very Low
imagery 5 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
metalloproteinase 4 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
Glutamate 2 5.00 Very Low Very Low Very Low
Sicca syndrome 1 5.00 Very Low Very Low Very Low
Neuropeptide 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Microsatellite Instability 7 99.04 Very High Very High Very High
Thyroid Neoplasm 330 98.60 Very High Very High Very High
Melanoma 19 98.36 Very High Very High Very High
Cancer 151 97.48 Very High Very High Very High
Apoptosis 8 95.56 Very High Very High Very High
Carcinoma 50 94.56 High High
Fatigue 1 85.28 High High
Disease 107 79.92 Quite High
Exanthema 3 67.00 Quite High
Diarrhoea 4 65.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas.

Negative_regulation (inhibitor) of BRAF associated with melanoma
1) Confidence 0.42 Published 2010 Journal J Transl Med Section Title Doc Link PMC2917408 Disease Relevance 0.20 Pain Relevance 0
Loss of heterozygosity, BRAF and KRAS mutations and microsatellite instability analysis
Negative_regulation (Loss) of BRAF associated with microsatellite instability
2) Confidence 0.33 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.34 Pain Relevance 0.03
Utilizing an orthotopic anaplastic thyroid carcinoma xenograft model in nude mice, Kim et al have shown that sorafenib, a multikinase inhibitor of RTK, VEGFR, and BRAF kinase, inhibits proliferation of ATC cell lines and inhibits tumor angiogenesis via induction of endothelial apoptosis (Kim et al 2007).
Negative_regulation (inhibitor) of BRAF in thyroid associated with thyroid neoplasm, cancer and apoptosis
3) Confidence 0.33 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 1.11 Pain Relevance 0
Sorafenib, a multitargeted small molecule kinase inhibitor, including the VEGF receptor and BRAF kinase, has also been evaluated in patients with thyroid cancer.
Negative_regulation (kinase) of BRAF in thyroid associated with thyroid neoplasm
4) Confidence 0.28 Published 2010 Journal Journal of Thyroid Research Section Body Doc Link PMC2956973 Disease Relevance 0.84 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox